Leukemia, Myelocytic, Acute Clinical Trial
Official title:
Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.
Considerable progress has been made in the induction therapy of acute myeloid leukemia
(AML); however, current therapeutic results are still unsatisfactory in those with relapsed
disease. The purine nucleoside analogue cladribine (2-chlorodeoxyadenosine, 2-CdA) has been
shown to be a safe and active agent in acute myeloid leukemia. Synergistic interaction
between cladribine and cytarabine has been demonstrated in preclinical and clinical studies.
The current multicenter phase II study was initiated to evaluate the efficacy and toxicity
of cladribine, high-dose cytarabine, and idarubicin in the treatment of patients with
relapsed AML. Adult patients of all age groups can be enrolled in the trial, but elderly
patients will be treated with a less dose-intensive regimen.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
| Completed |
NCT01716793 -
Risk-adapted Therapy for Adult Acute Myeloid Leukemia.
|
Phase 2 | |
| Terminated |
NCT00152594 -
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
|
Phase 3 | |
| Completed |
NCT01723657 -
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT01034592 -
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
|
N/A | |
| Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
| Recruiting |
NCT00449319 -
AML Treatment in Untreated Adult Patients
|
N/A | |
| Completed |
NCT00186381 -
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
|
Phase 2 | |
| Completed |
NCT00962767 -
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
|
Phase 3 | |
| Completed |
NCT01756118 -
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
|
Phase 1 | |
| Terminated |
NCT01339910 -
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
|
Phase 3 | |
| Completed |
NCT00201240 -
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
|
Phase 2 | |
| Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
| Terminated |
NCT00446303 -
A Phase II Study of Maintenance With Azacitidine in MDS Patients
|
Phase 2 | |
| Completed |
NCT00044486 -
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
|
Phase 3 | |
| Active, not recruiting |
NCT02158858 -
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00286845 -
Use of the MiCK Assay for Apoptosis in AML
|
Phase 1 | |
| Completed |
NCT00251368 -
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
|
Phase 1 | |
| Terminated |
NCT00048100 -
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
|
Phase 1 | |
| Recruiting |
NCT02895412 -
Infection and Tumour Antigen Cellular Therapy
|
Phase 1 |